GLP-1RA has been placed prominently in the international recommendations for the treatment of T2D as the first injectable agent before insulin due to the advantageous outcomes in cardiovascular safety studies that demonstrated a reduction of the combined cardiovascular endpoint three-component major adverse cardiovascular event (MACE-3
Patients who switched from semaglutide to orforglipron maintained a mean 79.3% of their body weight reduction compared with the placebo arm which maintained a mean 37.6% of their weight loss
Paradoxically, this increase has been associated with improved all-cause mortality as well as cardiovascular mortality, according to a post hoc analysis of the PROactive trial (259)
You feel full, then uncomfortable, then nauseated
The GLP-1 patches advertised online are dietary supplements, not pharmaceuticals, and they contain none of the active GLP-1 drug ingredients like semaglutide or tirzepatide
Diabetics should monitor blood glucose more frequently during the first month and discuss the addition with their endocrinologist